Close Menu

stock offering

NEW YORK (GenomeWeb News) – Foundation Medicine has filed with the US Securities and Exchange Commission to sell up to $150 million of its common stock in a public offering.

NEW YORK (GenomeWeb News) – Nanosphere announced after the close of the market on Tuesday an agreement to sell up to $30 million of shares of its common stock to investment fund Aspire Capital.

Arrowhead Research this week announced that it will sell 5.5 million shares of its common stock at $18.95 apiece for gross proceeds of $104 million.

Correction: The story has been updated to include the correct net proceed amount from the sale. NEW YORK (GenomeWeb News) – Fluidigm said after the close of the market on Tuesday it has closed on the sale of about $201.3 million of senior convertible notes.

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market on Tuesday it has increased the amount of convertible senior notes it is offering and has priced them.

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market on Monday that it plans to offer $250 million aggregate principal amount of convertible senior notes due 2021.

NEW YORK (GenomeWeb News) – NanoString Technologies has priced the follow-on public offering of its common stock at $18.50 per share.

NEW YORK (GenomeWeb News) – Atossa Genetics today priced its public offering of 5.8 million units at $2.40 per unit, saying it anticipates raising $14 million in gross proceeds.

NEW YORK (GenomeWeb News) – NanoString Technologies said after the close of the market Tuesday that it has launched a follow-on public offering of $55 million of common stock.

NEW YORK (GenomeWeb News) – CombiMatrix today said it has closed its public offering of 12,000 units of Series D convertible preferred stock and warrants, raising $12 million in gross proceeds.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.